Coronavirus
U.S. Orders 600K Doses of an Omicron Antibody Treatment
The U.S. is buying another 600,000 doses of a monoclonal antibody treatment from GlaxoSmithKline and Vir Biotechnology, the companies said, as the Biden administration looks to bolster treatment options.
The GSK and Vir antibody treatment is the only one of three monoclonal antibody treatments that is thought to work well against the omicron variant.
The deal brings the total doses purchased worldwide to 1.7 million, GSK said. It did not disclose a price for the order. The doses will be delivered throughout the first quarter of 2022, according to the company.
